Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.

Biotechnology

Convelo Therapeutics

Derrick Rossi

Drew Adams

Paul Tesar

Samantha Stubblefield

Edmond Mok

Dan Factor

Brad Lang

The Leadership Team at Convelo Therapeutics is responsible for setting the strategic direction and vision of the company, overseeing research and development initiatives, and ensuring the successful advancement of its pioneering therapies for neurological diseases. Comprising key executives with expertise in research, operations, and discovery, this team collaborates to drive innovation, foster partnerships, and navigate the complexities of bringing new regenerative medicines to market while prioritizing patient needs.

Leadership Team

Scientific Research Team

Leadership Team

About

Team members

Other teams at Convelo Therapeutics

Scientific Research Team